HYB0:F:F-HOYA CORP. ADR/ 1 O.N. (EUR)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 110

Change

+2.00 (+1.85)%

Market Cap

USD 36.89B

Volume

40.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-03 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
IUI1:F Intuitive Surgical Inc

-1.05 (-0.29%)

USD 128.13B
ESLC:F ESSILORLUXOTTICA 1/2/O.N.

-1.00 (-0.97%)

USD 95.93B
ESL:F EssilorLuxottica Société ano..

+1.60 (+0.77%)

USD 92.21B
BOX:F Becton Dickinson and Company

-0.70 (-0.32%)

USD 64.97B
HYB:F HOYA Corporation

-2.30 (-2.00%)

USD 38.31B
RMEA:F Resmed Inc DRC

N/A

USD 29.63B
RME:F ResMed Inc

-3.20 (-1.58%)

USD 29.14B
CBHD:F Coloplast A/S

+1.20 (+1.07%)

USD 28.11B
CBH:F COLOPLAST SP.ADR 1/10 DK1

-0.10 (-0.90%)

USD 25.50B
WPS:F West Pharmaceutical Services I..

+2.80 (+0.87%)

USD 24.79B

ETFs Containing HYB0:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain 12.82% 83% B 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.82% 76% C+ 59% D-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 4.00% 64% D 62% D
Dividend Return 4.00% 58% F 56% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 7.96% 84% B 87% B+
Risk Adjusted Return 50.25% 85% B 78% C+
Market Capitalization 36.89B 94% A 95% A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.